AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (868.9 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Nuclear pore complex protein RANBP2 and related SUMOylation in solid malignancies

Xinning Yua,1Huatao Wua,1Zheng Wub,cYangzheng Lanb,cWenjia Chenb,cBingxuan WuaYu DengaJing Liub,c( )
Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China
The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China
Department of Physiology, Shantou University Medical College, Shantou, Guangdong 515041, China

1 These authors contributed equally to this work.

Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA)

Show Author Information

Abstract

The growing interest in post-translational protein modification, particularly in SUMOylation, is driven by its crucial role in cell cycle regulation. SUMOylation affects various cell cycle regulators, including oncogenes, suggesting its relevance in cancer. SUMO E3 ligases are pivotal in this process, exhibiting diverse functionalities through structural domains and subcellular localizations. A less-explored SUMO E3 ligase, RANBP2, a component of the vertebrate nuclear pore complex, emerges as a central player in cellular cycle processes, as well as in tumorigenesis. The current studies illuminate the importance of RANBP2 and underscore the need for more extensive studies to validate its clinical applicability in neoplastic interventions. Our review elucidates the significance of RANBP2 across various types of malignancies. Additionally, it delves into exploring RANBP2 as a prospective therapeutic target for cancer treatment, offering insights into the avenues that scholars should pursue in their subsequent research endeavors. Thus, further investigation into RANBP2’s role in solid tumorigenesis is eagerly awaited.

References

【1】
【1】
 
 
Genes & Diseases
Article number: 101407

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Yu X, Wu H, Wu Z, et al. Nuclear pore complex protein RANBP2 and related SUMOylation in solid malignancies. Genes & Diseases, 2025, 12(4): 101407. https://doi.org/10.1016/j.gendis.2024.101407

376

Views

3

Downloads

0

Crossref

1

Web of Science

0

Scopus

0

CSCD

Received: 09 February 2024
Revised: 28 April 2024
Accepted: 21 June 2024
Published: 04 September 2024
© 2024 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).